PLoS ONE (Jan 2023)

Screening and hospitalization of breast and cervical cancer in Brazil from 2010 to 2022: A time-series study.

  • Haryelle Náryma Confessor Ferreira,
  • Gustavo Nepomuceno Capistrano,
  • Thiffany Nayara Bento de Morais,
  • Ketyllem Tayanne da Silva Costa,
  • Ana Luiza Santos Quirino,
  • Roberta Letícia Pimentel da Costa,
  • Fábia Barbosa de Andrade

DOI
https://doi.org/10.1371/journal.pone.0278011
Journal volume & issue
Vol. 18, no. 10
p. e0278011

Abstract

Read online

In Brazil, during the pandemic caused by COVID-19, screening for breast and cervical cancers was postponed or interrupted due to the prevailing health conditions. These neoplasms, however, are responsible for high morbidity and mortality among women in Brazil and have a major impact on the quality of life of this population and public health. Thus, this study aims to evaluate the epidemiological behavior of hospitalization for cervical and breast cancer in Brazilian women, as well as the trend of screening tests of breast and cervical cancer in the years 2010 to 2022 according to the regions of Brazil. This is ecological research of time series, based on secondary data obtained from information systems of the country, about hospital admissions for breast and cervical cancer and screening methods used for these tumors. The data were analyzed in the Joinpoint Regression Program, to obtain the linear regression and temporal analysis of the variables. As a result, between 2010 and 2022, the rates of mammography varied from 36 to 71 exams, while in the pap smear, the variations were 126 and 226 cytopathological exams per 1000 women. Hospitalizations for these cancers peaked in 2019, with 48 hospitalizations for cervical cancer per 100,000 women and 147 hospitalizations for breast cancer for the same population. For both, in the pandemic years, between 2020 and 2022, there is a decrease in Brazil and in all its regions. As for the tracking of these diseases, it was observed that the performance of mammograms and preventive tests showed a similar behavior, in which there is a higher supply of these tests until 2019 and a drop during the pandemic period. This leads to the conclusion that even though Brazil has several policies for the screening of these diseases, there is still instability in the offering of these tests and that there was instability in this area during the pandemic.